Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 4:33 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1225–1248 of 1,868 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: BE-FAST Clear all

Conditions: Diabetes Mellitus, Type 1
Interventions: Afrezza, insulin degludec, Rapid-acting Insulin Analog, Basal Insulin; Biological
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 19
States / cities: Loma Linda, California • Santa Barbara, California • Aurora, Colorado + 15 more

Conditions: Breast Cancer Prevention, Mammographic Density
Interventions: Ultrasound-guided core needle biopsy, Denosumab, Blood draw, Calcium, Vitamin D; Procedure · Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 35 Years and older · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Autoimmune Hepatitis
Interventions: LiverMultiscan; Device
Lead sponsor: Perspectum; Industry
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Major Depression
Interventions: High intensity whole-body infrared heating, Low intensity whole-body infrared heating, Functional Magnetic Resonance Imaging (fMRI) and electrocardiogram (EKG), Questionnaires; Device · Other
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 30 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Diabetes Mellitus, Type 2
Interventions: Placebo, Metformin, DA-1241; Drug
Lead sponsor: Dong-A ST Co., Ltd.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Muscle Hypertrophy, Healthy and Well-Trained Men and Women
Interventions: Time Restricted Eating, Normal Feeding, Resistance Training, Whey Protein; Other · Dietary Supplement
Lead sponsor: California State University, Fullerton; Other
Eligibility: 18 Years to 35 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Fullerton, California

Conditions: Asthma
Interventions: 10 mg tablet of montelukast (Singulair); Drug
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 7 Years to 35 Years
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Sleep Apnea, Opioid Use, Sleep Disordered Breathing
Interventions: Hyperoxia, Acetazolamide; Other · Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 89 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Diabetes Mellitus
Interventions: Patient Relationship Management (PRM) Program; Behavioral
Lead sponsor: Denver Health and Hospital Authority; Other
Eligibility: 18 Years to 76 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Colo-rectal Cancer, Polyp of Colon, Adenomatous Polyps
Interventions: EndoVigilant CAD Software; Device
Lead sponsor: EndoVigilant Inc; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 2
States / cities: Palo Alto, California • Greenbelt, Maryland

Conditions: Pre-op Gastric Emptying
Interventions: Not listed
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Breast Carcinoma, Colorectal Carcinoma, Lung Carcinoma, Metastatic Malignant Neoplasm in the Breast, Metastatic Malignant Neoplasm in the Colon, Metastatic Malignant Neoplasm in the Lung, Metastatic Malignant Neoplasm in the Rectum, Pancreatic Carcinoma
Interventions: 18F-αvβ6-BP; Drug
Lead sponsor: Julie L. Sutcliffe, Ph.D; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Ischemic Heart Disease
Interventions: Regadenoson; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Treatment Resistant Depression
Interventions: Active TBS-DLPFC, Sham TBS-DLPFC; Device
Lead sponsor: Stanford University; Other
Eligibility: 22 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Stanford, California

Conditions: Seborrheic Dermatitis
Interventions: Biopsy; Procedure
Lead sponsor: Boston University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Obesity
Interventions: Menu edited; Other
Lead sponsor: Carnegie Mellon University; Other
Eligibility: 18 Years and older
Enrollment: 309 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania

Conditions: Type 2 Diabetes
Interventions: telehealth-based clinical pharmacy intervention; Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 75 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Ankle Sprain
Interventions: Small amplitude (Grade IV) mobilization, High velocity, low amplitude (Grade V) mobilization; Other
Lead sponsor: Creighton University; Other
Eligibility: 19 Years to 45 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Epilepsy, Traumatic, Brain Injuries, Traumatic
Interventions: Home Based Self-management and Cognitive Training Changes lives in post traumatic epilepsy (HOBSCOTCH-PTE), HOBSCOTCH-PTE for Caregivers; Behavioral
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Diabetes type1, Diabetes Mellitus, Type 1, Diabetes, Autoimmune, Diabetes Mellitus, Distress, Emotional
Interventions: ReCharge, TakeCharge; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 30 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Coronary Artery Disease
Interventions: Invasive Cardiac Catheterization (ICA), Coronary Computed Tomographic Angiogram (CCTA), Dynamic Cardiac Positron Emission Tomography (dPET); Procedure
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 3
States / cities: Atlanta, Georgia • Roslyn, New York

Conditions: Raynaud, Scleroderma
Interventions: Fasudil; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Migraine, Cluster Headache, Trigeminal Autonomic Cephalgia, Hemicrania Continua, Paroxysmal Hemicrania, SUNCT, Short-Lasting Unilateral Neuralgiform Headache With Conjunctival Injection and Tearing
Interventions: Oral capsaicin, Topical capsaicin, Intranasal capsaicin, Cold Water Irrigation, Medical Air, Low Flow Oxygen, High Flow Oxygen; Drug · Other
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 371 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Type 2 Diabetes Mellitus
Interventions: Lixisenatide (AVE0010), Placebo, Insulin glargine, Pen auto-injector, Metformin, Thiazolidinedione (TZD); Drug · Device
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 446 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 23
States / cities: Mesa, Arizona • Hot Springs, Arkansas • Little Rock, Arkansas + 19 more

Search by objective public record fields.

INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes

RANKL Inhibition and Breast Tissue Biomarkers

AIH Risk Stratification With Multiparametric MRI

The Brain on Whole Body Hyperthermia: A Neuroimaging Study

A Study To Evaluate The Safety,Tolerability, PK and PD Of DA-1241 In Healthy Male Subjects

Time-Restricted Eating and Muscle Hypertrophy

Genotype Stratified Pharmacokinetic Study of Montelukast

Sleep Disordered Breathing With Opioid Use

Chronic Care Management/Patient Relationship Management Proof of Concept

Computer Aided Detection of Polyps During Colonoscopy Procedures

Residual Gastric Content and GLP-1

First-in-Human Positron Emission Tomography Study Using the 18F-αvβ6-Binding-Peptide

Development of a PET-MR Myocardial Perfusion Examination Using Regadenoson

Rapid Acting Transcranial Magnetic Stimulation

Neurobiology of the Scalp in Seborrheic Dermatitis

Fast Food Photo Study

Rural Area Pharmacist Intervention for Diabetes

Effect of Joint Mobilization in the Treatment of Chronic Ankle Instability

HOme-Based Self-management and COgnitive Training CHanges Lives (HOBSCOTCH) -Post-Traumatic Epilepsy (PTE)

Pilot of Pragmatic Delivery of Behavioral Approaches to Reduce Diabetes Distress in Adults With Type 1 Diabetes

Quantification of Myocardial Blood Flow Using Dynamic PET/CTA Fused Imagery

A Rho-kinase Inhibitor (Fasudil) in the Treatment of Raynaud's Phenomenon

Pain Biomarker Study

24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine